PPARG and neoplasm: In contrast, PPAR-γ-agonisttreatment inhibited pathological choroidial and retinal neovascularization [53] and suppressed tumor growthand metastasis by inhibiting tumor angiogenesis in several primary tumors, inpart through decreasing VEGF-production by tumor cells and blocking the productionof angiogenic ELR+CXC-chemokines, mediated through antagonizing NF-kappaBactivation [54, 55].